Use of paclitaxel carried in solid lipid nanoparticles to prevent peritoneal fibrosis in rats.
Filipe M O SilvaPriscila O CarvalhoElerson C CostalongaRafael PepineliRaul Cavalcante MaranhãoIrene L NoronhaPublished in: PloS one (2022)
LDE-PTX was effective to prevent development of PF and preserve the PM filtration capacity in this rat model, with clear-cut actions on pro-fibrotic mechanisms. Thus, LDE-PTX can be candidate for future clinical trials as adjuvant to peritoneal dialysis to prevent PF development, since this preparation is devoid of toxicity as shown previously.
Keyphrases
- peritoneal dialysis
- end stage renal disease
- clinical trial
- early stage
- chronic kidney disease
- air pollution
- oxidative stress
- particulate matter
- randomized controlled trial
- idiopathic pulmonary fibrosis
- current status
- risk assessment
- mass spectrometry
- fatty acid
- simultaneous determination
- chemotherapy induced
- tandem mass spectrometry